retatrutide on the market ⚠️ Before you consider using retatrutide, know facts. has not completed the FDA approval process, there is no official assessment confirming its safety or quality. The risks are real: 🚫 Outlook for Obesity in 2026:

Cannabinoids, inflammation, and fibrosis

The dosages and protocols discussed are evidence-based but should be personalized under medical supervision, especially if you have existing health conditions or take medications

(This is based on when you started the medication not your current weight) BMI of 35 or higher when you started, OR BMI of 30 or higher AND a serious heart or kidney condition, OR BMI of 27 or higher AND a history of heart attack, stroke, or pre-diabetes 3

In the STEP 1 trial, participants receiving semaglutide 2.4 mg weekly experienced significant reductions in triglycerides (mean decrease of 15-20%) and total cholesterol compared with placebo

Every report to MHRA's Yellow Card scheme helps improve the safety of medicines and medical devices for all